Experimental gene injection aims to halt rare blindness in kids and adults

NCT ID NCT05616793

Recruiting now Disease control Sponsor: Opus Genetics, Inc Source: ClinicalTrials.gov ↗

First seen Jan 06, 2026 · Last updated May 08, 2026 · Updated 19 times

Summary

This study tests a gene therapy called OPGx-001 for people with vision loss caused by changes in the LCA5 gene. The treatment is a one-time injection under the retina. The main goals are to check safety and see if it can slow or stop vision from getting worse. The study includes 22 people aged 4 and older.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LCA5 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Retina Foundation of the Southwest
RECRUITING

Dallas, Texas, 75231, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Pennsylvania Perelman School of Medicine
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

LCA5